Mereo BioPharma Group plc
Last updated September 27, 2026
Organization details
- Legal name
- Mereo BioPharma Group plc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Year founded
- 2015
- Jurisdiction of incorporation
- United Kingdom
- Headquarters city
- London
- Headquarters country
- United Kingdom
- Fiscal year end
- December
- Ticker symbol
- MREO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001719714
- UK company number
- 09481161
Board of directors
-
Anders Ekblom · DirectorSince 2024
-
Anders Ekblom · DirectorSince 2015
-
Annalisa Jenkins · DirectorSince 2024
-
Daniel Shames · DirectorSince 2024
-
Daniel, Shames · DirectorSince 2022
-
Deepika Pakianathan · DirectorSince 2024
-
Deepika, Pakianathan · DirectorSince 2019
-
Denise Scots-Knight · Director · Chief Executive OfficerSince 2024
-
Denise Vera, Scots-Knight · DirectorSince 2015
-
Jeremy Bender · DirectorSince 2024
-
Jeremy, Bender · DirectorSince 2020
-
Justin Hunter Roberts · DirectorSince 2024
-
Justin Roberts · DirectorSince 2022
-
Marc J. Yoskowitz · DirectorSince 2024
-
Marc Yoskowitz · DirectorSince 2022
-
Michael S. Wyzga · DirectorSince 2024
-
Michael Wyzga · DirectorSince 2019
-
Pierre Jacquet · DirectorSince 2024
-
Pierre, Jacquet · DirectorSince 2021
Former directors
-
Abdul Hafeez, Mullick · Director2022 – 2022
-
Annalisa, Jenkins · Director2022 – 2026
-
Anne Philomena Hyland · Director2022 – 2022
-
Brian, Schwartz · Director2020 – 2022
-
Frank, Armstrong · Director2015 – 2019
-
Kunal Kashyap · Director2015 – 2021
-
Paul Blackburn · Director2015 – 2020
-
Peter James Jonathan Bains · Director2015 – 2021
-
Peter John, Fellner · Director2015 – 2022
-
Richard Crispin Morgan Jones · Director2017 – 2020
-
Richard Edward Bungay · Director2016 – 2016
Chief executives
Denise Scots-Knight
· Chief Executive Officer
Dates unknown
Board connections
5 of this board's directors also sit on 11 other boards. 11 are in the same sector.
-
Aura Biosciences Inc. Same sectorvia Jeremy Bender
-
Bicara Therapeutics Inc. Same sectorvia Jeremy Bender
-
COMPASS Pathways Plc Same sectorvia Annalisa Jenkins
-
Elanco Animal Health Incorporated Same sectorvia Denise Scots-Knight
-
Freenome Inc. Same sectorvia Deepika Pakianathan
-
Invivyd Inc. Same sectorvia Michael S. Wyzga
-
Karyopharm Therapeutics Inc. Same sectorvia Deepika Pakianathan
-
Skye Bioscience Inc. Same sectorvia Annalisa Jenkins
-
Tectonic Therapeutic Inc. Same sectorvia Annalisa Jenkins
-
Tvardi Therapeutics Inc. Same sectorvia Michael S. Wyzga
-
X4 Pharmaceuticals Inc. Same sectorvia Michael S. Wyzga
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 13, 2024 | Denise Scots-Knight Director, Officer (Chief Executive Officer) | Open-market sale | −60,046 | $4.22 | $253,394 |
| Sep 13, 2024 | Lewicki John A. Officer (Chief Scientific Officer) | Open-market sale | −10,937 | $4.22 | $46,154 |
| Sep 13, 2024 | Sermon Charles Officer (General Counsel) | Open-market sale | −20,946 | $4.22 | $88,392 |
| Sep 13, 2024 | Fox Christine Ann Officer (Chief Financial Officer) | Open-market sale | −19,158 | $4.22 | $80,847 |
| Sep 13, 2024 | Hughes-Wilson Alexandra Officer (See Remarks) | Open-market sale | −16,304 | $4.22 | $68,803 |
| Sep 13, 2024 | Hughes-Wilson Alexandra Officer (See Remarks) | Open-market sale | −84,008 | $4.22 | $354,514 |
| Sep 12, 2024 | Denise Scots-Knight Director, Officer (Chief Executive Officer) | Open-market sale | −28,611 | $4.47 | $127,891 |
| Sep 12, 2024 | Lewicki John A. Officer (Chief Scientific Officer) | Open-market sale | −5,212 | $4.47 | $23,298 |
| Sep 12, 2024 | Sermon Charles Officer (General Counsel) | Open-market sale | −9,980 | $4.47 | $44,611 |
| Sep 12, 2024 | Fox Christine Ann Officer (Chief Financial Officer) | Open-market sale | −9,128 | $4.47 | $40,802 |
| Sep 12, 2024 | Hughes-Wilson Alexandra Officer (See Remarks) | Open-market sale | −7,769 | $4.47 | $34,727 |
| Sep 12, 2024 | Hughes-Wilson Alexandra Officer (See Remarks) | Open-market sale | −40,029 | $4.47 | $178,930 |
| Sep 11, 2024 | Sermon Charles Officer (General Counsel) | Option exercise | +65,600 | — | — |
| Sep 11, 2024 | Fox Christine Ann Officer (Chief Financial Officer) | Option exercise | +60,000 | — | — |
| Sep 11, 2024 | Lewicki John A. Officer (Chief Scientific Officer) | Option exercise | +46,000 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Akanda Corp.
Nasdaq: AKAN · New Romney, United Kingdom
Organization
Akari Therapeutics plc
Nasdaq: AKTX · Tampa, United Kingdom
Organization
AstraZeneca PLC
NYSE: AZN · Cambridge, United Kingdom
Organization
Autolus Therapeutics plc American Depositary Share
Nasdaq: AUTL · London, United Kingdom
Organization
Questions about Mereo BioPharma Group plc
Who is the CEO of Mereo BioPharma Group plc?
Denise Scots-Knight is Mereo BioPharma Group plc's Chief Executive Officer.
How many directors are on Mereo BioPharma Group plc's board?
Mereo BioPharma Group plc's board has 19 directors: Anders Ekblom, Anders Ekblom, Annalisa Jenkins, Daniel Shames, Daniel, Shames, Deepika Pakianathan, Deepika, Pakianathan, Denise Scots-Knight, Denise Vera, Scots-Knight, Jeremy Bender and 9 others.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="mereo-biopharma-group-plc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.